Concepedia
Statistics
Publications
6
Citations
1.1K
H-Index
Active since
2014
Affiliations
BioNTech (United States)(Current)
University of California, Los Angeles
Dana-Farber Cancer Institute
Harvard University
Dana-Farber Brigham Cancer Center
Meghan E. Bushway is an author at BioNTech (United States) specializing in cancer immunotherapy, immunology, and oncology.
Publications per year
2014–2023
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer
Patrick A. Ott, Siwen Hu‐Lieskovan, Bartosz Chmielowski et al. · Cell · 2020 · 743 citations · Full text
Medicine, Clinical Sciences, Oncology +17
Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer
Mark M. Awad, Ramaswamy Govindan, Kristen N. Balogh et al. · Cancer Cell · 2022 · 222 citations
Medicine, Immunology, Oncology +16
Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1
Asaf Poran, Julian Scherer, Meghan E. Bushway et al. · Cell Reports Medicine · 2020 · 48 citations · Full text
Life Sciences, Immunology, Oncology +17
Morphological and Phenotypic Analyses of the Human Placenta Using Whole Mount Immunofluorescence1
Meghan E. Bushway, Scott A. Gerber, Bruce M. Fenton et al. · Biology of Reproduction · 2014 · 27 citations · Full text
Life Sciences, Developmental Biology, Obstetrics +17
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial
Ai‐Min Hui, Jingxin Li, Li Zhu et al. · The Lancet Regional Health - Western Pacific · 2022 · 16 citations · Full text
Veterinary Medicine, Immunology, Immunization +15
1–5 of 6